Fasting plus diabetes drug may shrink breast tumors before surgery
NCT ID NCT05023967
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This study looks at whether combining a nightly fast (time-restricted eating) with the diabetes drug metformin can reduce breast cancer cell growth in women with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). About 120 participants will follow the fasting schedule and take metformin before their planned surgery. The goal is to see if this approach lowers tumor activity and improves markers linked to cancer risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
European Institute of Oncology
Milan, 20141, Italy
-
Galliera Hospital
Genoa, 16128, Italy
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.